regrelor disodium
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2004 (NCT00099450)
Timeline
Indications
Mechanism of action
- Purinergic receptor P2Y12ANTAGONIST
P2RY12 antagonist
Phase 2 study terminated, possibly due to adverse effects.
Chemistry & pharmacology
Loading structure…
SMILES
CCNC(=O)Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@H]2O[C@H](/C=C/c3ccccc3)O[C@H]21- Mol. weight
- 532.45 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1162175 ↗
- ChEMBLCHEMBL261244 ↗
Also known as
- ins50589
- ins50589
- ins50589
- ins 50589
- ins-50589
- ins-50589
- ins-50589
- regrelor
- regrelor
- regrelor disodium
- regrelor disodium
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00316212 | Phase 2 | Apr 1, 2006 | Merck |
| NCT00099450 | Phase 1 | Dec 1, 2004 | Merck |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 2 | 2 | 2 | 2004 |
1 organizations
Page 1 / 1